Jon is a Partner at Medicxi and has been with the firm since its inception in 2016. Prior to joining Medicxi, Jon was an Associate at Index Ventures for two years, having joined in 2014. He led Medicxi’s investment in Synthorx and currently serves on the boards of a number of portfolio companies, including Palladio Biosciences, Xenikos, Z-Factor, UltraHuman and Sydnexis. Jon was also previously a director of Impact Biomedicines (acquired by Celgene).
Prior to Index, Jon was a life sciences strategy consultant at ClearView Healthcare Partners.
Jon received a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill and conducted postdoctoral research at MIT.